Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi ; 39(11): 851-854, 2021 Nov 20.
Article in Chinese | MEDLINE | ID: mdl-34886647

ABSTRACT

Objective: To explore the main risk factors and to assess the risk of thyroid (131)I exposure among nuclear medical workers. Methods: From March to October in 2019, cluster sampling was adopted to collect the number of (131)I automatic packer and patients treated for thyroid cancer, hyperthyroidism and liven cancer used (131)I, the practicing categories, job rotation and (131)I operation condition of nuclear medical staff were also investegated in the 21 nuclear medicine hospitals in Fujian Province that carried out (131)I nuclide diagnosis and treatment in 2018. (131)I aerosol and personnel thyroid (131)I were measured in 20 hospitals using (131)I for thyroid cancer or hyperthyroidism. The main risk factors leading to thyroid (131)I exposure of nuclear medical staff were found and aninternal exposure risk assessment model was established. Results: The detection rate of (131)I aerosol and personnel thyroid (131)I were 80.0% (16/20) and 25.5% (62/243) in 20 hospitals. The situation of packaging and administration about (131)I in the nearly 10 effective half-life, the concentration of (131)I aerosol in the nuclear medicine workplace, the number of patients treated with (131)I for thyroid cancer or hyperthyroidism were the main risk factors leading to thyroid (131)I internal exposure (OR=5.857, 6.808, 1.983, 1.150, P<0.05) . Conclusion: (131)I exposure is common among nuclear medical workers, attention should be paid to the protection of internal radiation, strengthen the control of main risk factors, so as to reduce the risk of internal radiation.


Subject(s)
Occupational Exposure , Thyroid Gland , Humans , Iodine Radioisotopes , Medical Staff , Risk Assessment
2.
Surg Endosc ; 32(8): 3548-3556, 2018 08.
Article in English | MEDLINE | ID: mdl-29572630

ABSTRACT

BACKGROUND: Premedication in upper gastrointestinal endoscopy for higher lesions detection rate has not been well studied so far. This study aimed to confirm whether premedication could improve the detection rate of early cancer or precancerous lesions and mucosal visibility. METHOD: From July 2015 to December 2015, 7200 participants from 6 centers were screened by endoscopy with one of the 4 following premedications randomly: (1) water (group D); (2) pronase (group A); (3) simethicone (group B); (4) pronase and simethicone (group C). Early cancer and precancerous lesions detection rates were taken as the primary endpoints, and mucosal visibility was taken as the secondary endpoint. They were compared among four groups to determine different premedication effects in terms of different anatomical sites. Trial was registered at Chinese Clinical Trial Registry; the registration number is ChiCTR-IOR-17010985. RESULTS: The upper gastrointestinal overall precancerous lesion detection rates among four groups were 8.7, 8.4, 10.0, and 10.3%, the overall early cancer detection rates were 1.3, 1.4%, 1.5, and 1.6%, both without significant difference (p = 0.138 and 0.878). However, the visibility score distributions between control group (D) and premedication groups (A, B, and C) were all statistically significant, with all anatomical sites p values < 0.001. Subgroup analyses, from 2 centers without screening before, also showed significant difference in esophageal (3.9, 3.3, 4.5, and 8.4% with p = 0.004) and overall (7.0, 5.5, 7.3, and 12.0% with p = 0.004) precancerous lesion detection rate. CONCLUSIONS: Premedication with pronase and simethicone may not increase lesion detection rates but could significantly increase the upper gastrointestinal mucosal visibility.


Subject(s)
Antifoaming Agents/therapeutic use , Early Detection of Cancer/methods , Endoscopy, Gastrointestinal , Expectorants/therapeutic use , Gastrointestinal Neoplasms/diagnostic imaging , Precancerous Conditions/diagnostic imaging , Premedication/methods , Adult , Aged , Double-Blind Method , Drug Administration Schedule , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Mucous Membrane/diagnostic imaging , Pronase/therapeutic use , Simethicone/therapeutic use
3.
Nat Commun ; 9(1): 724, 2018 02 20.
Article in English | MEDLINE | ID: mdl-29463872

ABSTRACT

The range of potential applications of compact laser-plasma ion sources motivates the development of new acceleration schemes to increase achievable ion energies and conversion efficiencies. Whilst the evolving nature of laser-plasma interactions can limit the effectiveness of individual acceleration mechanisms, it can also enable the development of hybrid schemes, allowing additional degrees of control on the properties of the resulting ion beam. Here we report on an experimental demonstration of efficient proton acceleration to energies exceeding 94 MeV via a hybrid scheme of radiation pressure-sheath acceleration in an ultrathin foil irradiated by a linearly polarised laser pulse. This occurs via a double-peaked electrostatic field structure, which, at an optimum foil thickness, is significantly enhanced by relativistic transparency and an associated jet of super-thermal electrons. The range of parameters over which this hybrid scenario occurs is discussed and implications for ion acceleration driven by next-generation, multi-petawatt laser facilities are explored.

4.
Ann Oncol ; 28(9): 2086-2093, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-28911061

ABSTRACT

The International Agency for Research on Cancer (IARC) and the US National Cancer Institute (NCI) have initiated a series of cancer-focused seminars [Scelo G, Hofmann JN, Banks RE et al. International cancer seminars: a focus on kidney cancer. Ann Oncol 2016; 27(8): 1382-1385]. In this, the second seminar, IARC and NCI convened a workshop in order to examine the state of the current science on esophageal squamous cell carcinoma etiology, genetics, early detection, treatment, and palliation, was reviewed to identify the most critical open research questions. The results of these discussions were summarized by formulating a series of 'difficult questions', which should inform and prioritize future research efforts.


Subject(s)
Carcinoma, Squamous Cell , Esophageal Neoplasms , Internationality , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/therapy , Early Detection of Cancer , Esophageal Neoplasms/epidemiology , Esophageal Neoplasms/genetics , Esophageal Neoplasms/therapy , Esophageal Squamous Cell Carcinoma , Humans , Risk Factors
5.
Pharmacogenomics J ; 17(2): 204-208, 2017 03.
Article in English | MEDLINE | ID: mdl-26902539

ABSTRACT

Statins (HMG-CoA reductase inhibitors) lower low-density lipoprotein cholesterol (LDL-C) and prevent cardiovascular disease. However, there is wide individual variation in LDL-C response. Drugs targeting proprotein convertase subtilin/kexin type 9 (PCSK9) lower LDL-C and will be used with statins. PCSK9 mediates the degradation of LDL receptors (LDLRs). Therefore, a greater LDL-C response to statins would be expected in individuals with PCSK9 loss-of-function (LOF) variants because LDLR degradation is reduced. To examine this hypothesis, the effect of 11 PCSK9 functional variants on statin response was determined in 669 African Americans. One LOF variant, rs11591147 (p.R46L) was significantly associated with LDL-C response to statin (P=0.002). In the three carriers, there was a 55.6% greater LDL-C reduction compared with non-carriers. Another functional variant, rs28362261 (p.N425S), was marginally associated with statin response (P=0.0064).The effect of rs11591147 was present in individuals of European ancestry (N=2388, P=0.054). The therapeutic effect of statins may be modified by genetic variation in PCSK9.


Subject(s)
Cholesterol, LDL/blood , Dyslipidemias/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Pharmacogenomic Variants , Polymorphism, Single Nucleotide , Proprotein Convertase 9/genetics , Adult , Black or African American/genetics , Aged , Biomarkers/blood , Dyslipidemias/blood , Dyslipidemias/enzymology , Dyslipidemias/genetics , Female , Gene Frequency , Genetic Association Studies , Genotype , Humans , Male , Middle Aged , Pharmacogenetics , Phenotype , Risk Factors , Treatment Outcome , White People/genetics
6.
Pharmacogenomics J ; 16(3): 231-7, 2016 06.
Article in English | MEDLINE | ID: mdl-26169577

ABSTRACT

The most common side effect of angiotensin-converting enzyme inhibitor (ACEi) drugs is cough. We conducted a genome-wide association study (GWAS) of ACEi-induced cough among 7080 subjects of diverse ancestries in the Electronic Medical Records and Genomics (eMERGE) network. Cases were subjects diagnosed with ACEi-induced cough. Controls were subjects with at least 6 months of ACEi use and no cough. A GWAS (1595 cases and 5485 controls) identified associations on chromosome 4 in an intron of KCNIP4. The strongest association was at rs145489027 (minor allele frequency=0.33, odds ratio (OR)=1.3 (95% confidence interval (CI): 1.2-1.4), P=1.0 × 10(-8)). Replication for six single-nucleotide polymorphisms (SNPs) in KCNIP4 was tested in a second eMERGE population (n=926) and in the Genetics of Diabetes Audit and Research in Tayside, Scotland (GoDARTS) cohort (n=4309). Replication was observed at rs7675300 (OR=1.32 (1.01-1.70), P=0.04) in eMERGE and at rs16870989 and rs1495509 (OR=1.15 (1.01-1.30), P=0.03 for both) in GoDARTS. The combined association at rs1495509 was significant (OR=1.23 (1.15-1.32), P=1.9 × 10(-9)). These results indicate that SNPs in KCNIP4 may modulate ACEi-induced cough risk.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/adverse effects , Cough/chemically induced , Cough/genetics , Kv Channel-Interacting Proteins/genetics , Polymorphism, Single Nucleotide , Case-Control Studies , Computational Biology , Cough/ethnology , Databases, Genetic , Electronic Health Records , Female , Gene Frequency , Genetic Predisposition to Disease , Genome-Wide Association Study , Humans , Logistic Models , Male , Multivariate Analysis , Odds Ratio , Phenotype , Risk Assessment , Risk Factors , Scotland , United States
7.
Clin Pharmacol Ther ; 95(3): 331-8, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24096969

ABSTRACT

Efforts to define the genetic architecture underlying variable statin response have met with limited success, possibly because previous studies were limited to effect based on a single dose. We leveraged electronic medical records (EMRs) to extract potency (ED50) and efficacy (Emax) of statin dose-response curves and tested them for association with 144 preselected variants. Two large biobanks were used to construct dose-response curves for 2,026 and 2,252 subjects on simvastatin and atorvastatin, respectively. Atorvastatin was more efficacious, was more potent, and demonstrated less interindividual variability than simvastatin. A pharmacodynamic variant emerging from randomized trials (PRDM16) was associated with Emax for both. For atorvastatin, Emax was 51.7 mg/dl in subjects homozygous for the minor allele vs. 75.0 mg/dl for those homozygous for the major allele. We also identified several loci associated with ED50. The extraction of rigorously defined traits from EMRs for pharmacogenetic studies represents a promising approach to further understand the genetic factors contributing to drug response.


Subject(s)
Electronic Health Records , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hyperlipidemias/drug therapy , Hyperlipidemias/genetics , Algorithms , Alleles , Atorvastatin , Cholesterol, LDL/blood , Cohort Studies , Databases, Factual , Dose-Response Relationship, Drug , Genotype , Heptanoic Acids/administration & dosage , Heptanoic Acids/therapeutic use , Humans , Lipid Metabolism/drug effects , Lipid Metabolism/genetics , Lipids/blood , Phenotype , Polymorphism, Single Nucleotide , Pyrroles/administration & dosage , Pyrroles/therapeutic use , Randomized Controlled Trials as Topic , Simvastatin/administration & dosage , Simvastatin/therapeutic use
8.
Ann Oncol ; 23(11): 2983-2989, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22689178

ABSTRACT

BACKGROUND: Most cancers are due to modifiable lifestyle and environmental risk factors, and are potentially preventable. No studies have provided a systematic quantitative assessment of the burden of cancer mortality and incidence attributable to known risk factors in China. METHODS: We calculated the proportions of cancer deaths and new cases attributable to known risk factors in China, based on the prevalence of exposure around 1990 and national data on cancer mortality and incidence for the year 2005. RESULTS: Chronic infection is the main risk factor for cancer in China, accounting for 29.4% of cancer deaths (31.7% in men and 25.3% in women), followed by tobacco smoking (22.6% with 32.7% in men and 5.0% in women), low fruit intake (13.0%), alcohol drinking (4.4%), low vegetable intake (3.6%) and occupational exposures (2.7%). The remaining factors, including environmental agents, physical inactivity, the use of exogenous hormones and reproductive factors are each responsible for <1.0%. CONCLUSIONS: Modifiable risk factors explain nearly 60% of cancer deaths in China, with a predominant role of chronic infection and tobacco smoking. Our findings could provide a basis for cancer prevention and control programs aimed at reducing cancer risk in other developing countries.


Subject(s)
Neoplasms/epidemiology , Neoplasms/etiology , Alcohol Drinking/adverse effects , China/epidemiology , Chronic Disease , Environmental Exposure , Female , Food , Humans , Incidence , Infections/complications , Infections/epidemiology , Life Style , Male , Occupational Exposure/adverse effects , Prevalence , Risk Factors , Risk Reduction Behavior , Smoking/adverse effects
9.
Histol Histopathol ; 21(6): 627-32, 2006 06.
Article in English | MEDLINE | ID: mdl-16528673

ABSTRACT

BAC is a common pattern in conventional lung adenocarcinoma. In the past, however, there were no well-defined criteria for BAC. As a result, it was difficult to evaluate the prognosis on this type of lung adenocarcinoma. Though the 1999 WHO classification of BAC provides a useful framework, it does not provide detailed enough information to predict prognosis in lung adenocarcinomas with BAC feature. The aim of this study was to address the prognostic value of bronchioloalveolar carcinoma (BAC) component in lung adenocarcinoma. Ninety-one consecutive surgically treated patients with adenocarcinoma exhibiting various degrees of BAC features and complete follow-up records were retrospectively studied. According to the percentage of BAC component designed as less than 50%, 50%-79%, 80%-99%, and 100%, tumors were classified as type I, type II, type III, and type IV respectively. The overall 5-year survival rate was 64.84%. Multivariate analysis revealed that the four classified types are independent prognostic factors (P=0.0008), as is tumor stage (P=0.0000). The 5-year survival rates were 39.29%, 58.82%, 81.25%, 85.71% for the four classified types respectively, and were 88.89% for stage I, 46.15% for stage II, and 23.81% for stage III. However, the size of tumor (>2 cm) was significant only in the univariate analysis (P=0.0275). In the patients with tumor size exceeding 2 cm in diameter, the BAC component was also significant to predict prognosis (p=0.0008). In lung adenocarcinoma, the BAC component may prove to be useful to predict the outcome of the patients, and the percentage of BAC pattern and pathological stage appear to be two independent prognostic factors.


Subject(s)
Adenocarcinoma, Bronchiolo-Alveolar/diagnosis , Adenocarcinoma, Bronchiolo-Alveolar/pathology , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology , Adult , Age Factors , Aged , Cell Proliferation , Female , Histocytochemistry , Humans , Male , Middle Aged , Multivariate Analysis , Neoplasm Staging , Outcome Assessment, Health Care , Prognosis , Retrospective Studies , Sex Factors , Smoking , Survival Rate , World Health Organization
10.
Gut ; 54(6): 759-63, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15888779

ABSTRACT

BACKGROUND: Oesophageal squamous cell carcinoma (OSCC) is a common cancer worldwide and has a very high mortality rate. Squamous dysplasia is the precursor lesion for OSCC and it can be seen during routine endoscopy with Lugol's iodine staining. We aimed to examine the risk factors for squamous dysplasia and determine if a risk model could be constructed which would be useful in selecting apparently healthy subjects for endoscopic screening in a high risk population in Linzhou, People's Republic of China. SUBJECTS AND METHODS: In this cross sectional study, 724 adult volunteers aged 40-65 years were enrolled. All subjects completed a questionnaire regarding potential environmental exposures, received physical and dental examinations, and underwent upper endoscopy with Lugol's iodine staining and biopsy. Subjects were categorised as having or not having histologically proven squamous dysplasia/early cancer. Risk factors for dysplasia were examined using univariate and multivariate logistic regression. The utility of the final multivariate model as a screening tool was assessed using a receiver operating characteristics curve. RESULTS: We found that 230 of 720 subjects (32%) with complete data had prevalent squamous dysplasia. In the final multivariate model, more household members (odds ratio (OR) 1.12/member (95% confidence interval (CI) 0.99, 1.25)), a family history of cancer (OR 1.57 (95% CI 1.13-2.18)), higher systolic blood pressure OR 1.11/10 mm Hg (95% CI 1.03-1.19)), heating the home without a chimney (OR 2.22 (95% CI 1.27-3.86)), and having lost more but not all of your teeth (OR 1.91 for 12-31 teeth lost (95% CI 1.17-3.15)) were associated with higher odds of having dysplasia. Higher household income (OR 0.96/100 RMB (95% CI 0.91-1.00)) was associated with a lower odds of having dysplasia. Although we found several statistically significant associations, the final model had little ability to accurately predict dysplasia status, with maximum simultaneous sensitivity and specificity values of 57% and 54%, respectively. CONCLUSIONS: We found that risk factors for dysplasia were similar to those previously identified as risk factors for OSCC in this population. The final model did a poor job of identifying subjects who had squamous dysplasia. Other methods will need to be developed to triage individuals to endoscopy in this high risk population.


Subject(s)
Carcinoma, Squamous Cell/pathology , Esophageal Neoplasms/pathology , Esophagus/pathology , Precancerous Conditions/pathology , Adult , Aged , Biopsy/methods , Cross-Sectional Studies , Esophagoscopy/methods , Humans , Mass Screening/methods , Middle Aged , Observer Variation , Odds Ratio , Physical Examination , Risk Factors , Tooth Loss/etiology
11.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao ; 23(1): 78-82, 2001 Feb.
Article in Chinese | MEDLINE | ID: mdl-12905826

ABSTRACT

Recent epidemiology and laboratory studies indicate that regular taking of aspirin and other non-steroidal anti-inflammatory drugs(NSAIDs) may reduce the risk of colorectal, esophageal, stomach and pancreatic cancers and other digestive cancers. Thus, aspirin and other NSAIDs may be an effective chemoprevention agent for digestive cancers. On the other hand, this protection effort may be beneficial to the course of the intervention, regression and prevention of cancer lesions. The possible mechanism of NSAIDs chemoprevention may be: (1) reducing the synthesis of prostaglandin(PG) and inhibiting cyclo-oxygenase(COX) activity; (2) inducing apoptosis in epithelial cells of the gastro-intestinal origin; (3) obstructing signaling transduction pathways of COX and PG. Now, chemoprevention of NSAIDs has become focus of research on cancer secondary prevention, as its protective effects of chemoprevention of digestive cancer have been determined. NSAIDs, especially selective COX-2 inhibitor may be a novel useful chemoprevention agents for digestive cancer and their precursor lesions in future.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Gastrointestinal Neoplasms/prevention & control , Animals , Aspirin/pharmacology , Chemoprevention/methods , Cyclooxygenase 2 , Humans , Isoenzymes/drug effects , Isoenzymes/physiology , Membrane Proteins , Prostaglandin-Endoperoxide Synthases/drug effects , Prostaglandin-Endoperoxide Synthases/physiology
12.
Proc Natl Acad Sci U S A ; 93(20): 10984-9, 1996 Oct 01.
Article in English | MEDLINE | ID: mdl-8855295

ABSTRACT

Lipophosphoglycan (LPG) glycoconjugates from promastigotes of Leishmania were not able to induce the expression of the cytokine-inducible nitric oxide synthase (iNOS) by the murine macrophage cell line, J774. However, they synergize with interferon gamma to stimulate the macrophages to express high levels of iNOS. This synergistic effect was critically time-dependent. Preincubation of J774 cells with the LPG glycans 4-18 h before stimulation with interferon gamma resulted in a significant reduction in the expression of iNOS mRNA and of NO synthesis, compared with cells preincubated with culture medium alone. The regulatory effect on the induction of iNOS by LPG is located in the LPG phosphoglycan disaccharide backbone. Synthetic fragments of this backbone had a similar regulatory effect on NO synthesis. Further, the production of NO by activated macrophages in the present system was correlated directly with the leishmanicidal capacity of the cells. These data therefore demonstrate that LPG glycoconjugates have a profound effect on the survival of Leishmania parasites through their ability to regulate the expression of iNOS by macrophages.


Subject(s)
Glycosphingolipids/immunology , Leishmania major/immunology , Macrophages/immunology , Nitric Oxide Synthase/biosynthesis , Animals , Carbohydrate Sequence , Cytotoxicity, Immunologic , Gene Expression Regulation, Enzymologic/drug effects , Glycosphingolipids/chemistry , Immunity, Cellular/drug effects , Interferon-gamma/pharmacology , Leishmania major/chemistry , Macrophages/enzymology , Mice , Molecular Sequence Data , RNA, Messenger/genetics , Recombinant Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...